showed in ER-b/KRAS mutant mice models that the combination of an ER-b blocker, fulvestrant, with a pan-HER tyrosine kinase inhibitor dacomitinib had a synergistic anti-tumor effect in treating ER-b positive lung cancer. Here, ESR2 is linked to lung carcinoma.